Role of Tissue Factor Pathway Inhibitor-2 (TFPI-2) in Amelanotic Melanoma (C-32) Invasion

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2001 Jul 13

PMID 11448060

Citations 10

Authors

S D Konduri

A Tasiou

N Chandrasekar

G L Nicolson

J S Rao

Affiliations

Soon will be listed here.

Abstract

Human tissue factor pathway inhibitor-2 (TFPI-2), also known as placental protein (PP5) and matrix-associated serine protease inhibitor (MSPI), is a 32-kDa extracellular matrix (ECM) protein consisting of three tandomly arranged Kunitz-type domains that inhibits plasmin, trypsin, chymotrypsin, cathepsin G and plasma kallikrein but not urokinase and tissue-type plasminogen activators or thrombin. Earlier studies in our laboratory revealed that the production of TFPI-2 is reduced or absent during the tumor progression of human gliomas. In the present study, we investigated the role of TFPI-2 in the invasiveness of the amelanotic melanoma cell line C-32. We stably transfected C-32 cells with a vector capable of expressing TFPI-2 in a sense orientation (0.7 kb). TFPI-2 protein production was then determined by western blotting and the mRNA level by northern blotting in parental and stably transfected (vector and sense) clones. The levels of TFPI-2 protein and mRNA were significantly higher in the sense clones, but neither was detected in parental and vector control clones. In addition, in vitro Matrigel invasion/migration assays revealed that the invasive behavior of sense clones was inhibited compared with the behavior of parental and vector clones. This is the first study to show that the upregulation of TFPI-2 plays a significant role in reducing the invasive behavior of human amelanotic melanomas.

Citing Articles

Tissue factor pathway inhibitor-2 (TFPI-2)-an underappreciated partaker in cancer and metastasis.

Wojtukiewicz M, Mysliwiec M, Tokajuk A, Kruszewska J, Politynska B, Jamroze A Cancer Metastasis Rev. 2024; 43(4):1185-1204.

PMID: 39153052 PMC: 11554837. DOI: 10.1007/s10555-024-10205-7.

TFPI2 Promotes Perivascular Migration in an Angiotropism Model of Melanoma.

Mo J, Zhao X, Wang W, Zhao N, Dong X, Zhang Y Front Oncol. 2021; 11:662434.

PMID: 34249699 PMC: 8264799. DOI: 10.3389/fonc.2021.662434.

MicroRNA-23a acts as an oncogene in pancreatic carcinoma by targeting TFPI-2.

Wang W, Ning J, Tang Z, He Y, Yao L, Ye L Exp Ther Med. 2020; 20(5):53.

PMID: 32952643 PMC: 7485308. DOI: 10.3892/etm.2020.9181.

Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer.

Xu C, Wang H, He H, Zheng F, Chen Y, Zhang J BMC Cancer. 2013; 13:118.

PMID: 23497249 PMC: 3607852. DOI: 10.1186/1471-2407-13-118.

Tissue factor pathway inhibitor-2 inhibits the growth and invasion of hepatocellular carcinoma cells and is inactivated in human hepatocellular carcinoma.

Xu Y, Qin X, Zhou J, Tu Z, Bi X, Li W Oncol Lett. 2012; 2(5):779-783.

PMID: 22866126 PMC: 3408107. DOI: 10.3892/ol.2011.340.

References

Eitzman D, Krauss J, Shen T, Cui J, Ginsburg . Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood. 1996; 87(11):4718-22. View

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

Mueller B, Ruf W . Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest. 1998; 101(7):1372-8. PMC: 508714. DOI: 10.1172/JCI930. View

Fischer E, Riewald M, Huang H, Miyagi Y, Kubota Y, Mueller B . Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest. 1999; 104(9):1213-21. PMC: 409824. DOI: 10.1172/JCI7750. View

Muller M, Albrecht S, Golfert F, Hofer A, Funk R, Magdolen V . Localization of tissue factor in actin-filament-rich membrane areas of epithelial cells. Exp Cell Res. 1999; 248(1):136-47. DOI: 10.1006/excr.1999.4395. View

Iino M, Foster D, Kisiel W . Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol. 1998; 18(1):40-6. DOI: 10.1161/01.atv.18.1.40. View

Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y . Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer. 1996; 77(9):1877-83. DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1877::AID-CNCR18>3.0.CO;2-X. View

Yamamoto M, Sawaya R, Mohanam S, Bindal A, Bruner J, Oka K . Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res. 1994; 54(14):3656-61. View

Werling R, Zacharski L, Kisiel W, Bajaj S, Memoli V, Rousseau S . Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost. 1993; 69(4):366-9. View

10.

Ollivier V, Bentolila S, Chabbat J, Hakim J, de Prost D . Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood. 1998; 91(8):2698-703. View

11.

Dennis M, Lazarus R . Kunitz domain inhibitors of tissue factor-factor VIIa. I. Potent inhibitors selected from libraries by phage display. J Biol Chem. 1994; 269(35):22129-36. View

12.

Rao C, Reddy P, Liu Y, OToole E, Reeder D, Foster D . Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch Biochem Biophys. 1996; 335(1):82-92. DOI: 10.1006/abbi.1996.0484. View

13.

Mueller B, Reisfeld R, Edgington T, Ruf W . Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A. 1992; 89(24):11832-6. PMC: 50651. DOI: 10.1073/pnas.89.24.11832. View

14.

Petersen L, Bjorn S, Olsen O, Nordfang O, Norris F, Norris K . Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Eur J Biochem. 1996; 235(1-2):310-6. DOI: 10.1111/j.1432-1033.1996.0310f.x. View

15.

Towbin H, Staehelin T, Gordon J . Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979; 76(9):4350-4. PMC: 411572. DOI: 10.1073/pnas.76.9.4350. View

16.

Koshikawa N, Yasumitsu H, Umeda M, Miyazaki K . Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines. Cancer Res. 1992; 52(18):5046-53. View

17.

Rao C, Cook B, Liu Y, Chilukuri K, Stack M, Foster D . HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int J Cancer. 1998; 76(5):749-56. DOI: 10.1002/(sici)1097-0215(19980529)76:5<749::aid-ijc21>3.0.co;2-y. View

18.

Contrino J, Hair G, Kreutzer D, Rickles F . In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996; 2(2):209-15. DOI: 10.1038/nm0296-209. View

19.

Kwaan H . The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev. 1992; 11(3-4):291-311. DOI: 10.1007/BF01307184. View

20.

Sprecher C, Kisiel W, Mathewes S, Foster D . Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci U S A. 1994; 91(8):3353-7. PMC: 43575. DOI: 10.1073/pnas.91.8.3353. View